Clinical Trials Logo

Brain Tumor clinical trials

View clinical trials related to Brain Tumor.

Filter by:

NCT ID: NCT00597402 Completed - Glioblastoma Clinical Trials

Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas

Start date: July 2007
Phase: Phase 2
Study type: Interventional

Primary objective: To use overall survival to assess the efficacy of the combination of radiation therapy, temozolomide and Avastin followed by Avastin, temozolomide, and irinotecan in the treatment of grade IV malignant glioma patients following surgical resection. Secondary objective: To determine the progression-free survival following the combination of radiation therapy, temozolomide and Avastin followed by Avastin, temozolomide, and irinotecan. Exploratory Objective: To explore the relationship between biomarkers and outcome (overall survival and progression-free survival) among patients with grade IV malignant glioma treated with radiation therapy, temozolomide and Avastin followed by Avastin, temozolomide, and irinotecan. To describe the toxicity of radiation therapy,temozolomide and Avastin followed by Avastin, temozolomide, and irinotecan.

NCT ID: NCT00594633 Completed - Brain Tumor Clinical Trials

Adjunctive Donepezil Therapy and Genetic Risk Factors of Cognitive Dysfunction in Brain Tumor Survivors

Start date: October 2004
Phase: Phase 1
Study type: Interventional

A significant number of brain tumor patients who received radiation or chemotherapy have thinking problems as a result of their treatment. The purpose of this study is to find out if treatment with Aricept (donepezil) may improve some aspects of thinking abilities in patients with brain tumors who received radiation or chemotherapy. This research will also study whether persons having particular genes for a blood-borne substance called apolipoprotein E (APOE) are more likely to have thinking problems after radiation or chemotherapy treatment for their brain tumors. The findings of this study will help us find out whether Aricept can improve thinking abilities after cancer treatment, and whether some of the thinking difficulties may be in part related to having certain genes.

NCT ID: NCT00584883 Completed - Brain Tumor Clinical Trials

A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme

Start date: August 2003
Phase: Phase 1
Study type: Interventional

To determine the maximum tolerated dose of ABT 510 when administered concurrent with radiation therapy for patients with newly diagnosed glioblastoma multiforme.

NCT ID: NCT00503204 Completed - Brain Tumor Clinical Trials

Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour

Start date: September 2007
Phase: Phase 1
Study type: Interventional

This is a Phase I, open-label, multi-centre study designed to assess the safety and tolerability of Cediranib in combination with lomustine in patients with primary recurrent malignant brain tumour.

NCT ID: NCT00440570 Completed - Cancer Clinical Trials

A Study of Therapeutic Amplitude-modulated Electromagnetic Fields in Advanced Tumors

THBC001
Start date: October 2004
Phase: Phase 0
Study type: Interventional

In vitro studies suggest that low levels of amplitude-modulated electromagnetic fields may modify cell growth. We have identified specific frequencies that may block cancer cell growth. We have developed a device delivering low levels of amplitude-modulated electromagnetic fields. The device is connected to a spoon-like coupler, which is placed in the patient's mouth during treatment. We will conduct a feasibility study consisting of three daily ambulatory treatments until disease progression.

NCT ID: NCT00400816 Completed - Brain Tumor Clinical Trials

Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma

Start date: August 2005
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well temozolomide works in treating patients with newly diagnosed anaplastic oligodendroglioma or mixed oligoastrocytoma.

NCT ID: NCT00395863 Completed - Brain Tumor Clinical Trials

Multihance at 3 Tesla (3T) in Brain Tumors

Start date: November 2006
Phase: Phase 4
Study type: Interventional

Compare the efficacy of MultiHance and Magnevist

NCT ID: NCT00392119 Completed - Brain Tumor Clinical Trials

MR Guided Laser Interstitial Thermal Therapy for the "Minimal Invasive" Treatment of Brain Metastasis and Primary Brain Tumors

Start date: October 2006
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine if the stereotactic, MR guided, laser interstitial thermal therapy treatment technique can be safety and efficiently used for human brain metastasis and primary brain tumors.

NCT ID: NCT00362817 Completed - Brain Tumor Clinical Trials

Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases

Start date: October 2004
Phase: Phase 1/Phase 2
Study type: Interventional

Purpose: The primary objective of this study is to determine if chemotherapy with carboplatin and temozolomide significantly affects the response rates, or size of disease, in patients with brain metastases, originating from cancer in other parts of the body, compared to patients who have already been treated with radiation. Survival, causes of death, recurrence of disease in the central nervous system, toxicity, and quality of life will all be measured as secondary objective in this study.

NCT ID: NCT00336531 Completed - Neuroblastoma Clinical Trials

Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation

Start date: April 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to investigate whether the prophylactic use of itraconazole is a better option than empirical use of itraconazole in the management (prevention and treatment) of fungal infection associated with high-dose chemotherapy and autologous hematopoietic stem cell transplantation in children with high-risk solid tumor.